// App-Quantinova.ai

3426 : Time To Hematologic and Renal Improvements In aHUS Patients With Progressing Thrombotic Microangiopathy Treated With Eculizumab Over Two Years

Researchers

Presenter

  • Petra Muus

Principal Investigators

  • Camille L. Bedrosian

  • Richard R. Furman

  • Christophe Legendre

  • Chantel Loirat

Medical Centers

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

  • University Paris Descartes & Hopital Necker, Paris, France

  • Radboud University Medical Center, Njmegen, Netherlands

  • CHU Robert Debre, Reims, France

Locations

  • United States

  • France

  • Netherlands

Companies

  • Alexion Pharmaceutic

Study Components

Therapeutic Area

  • Nephrology

  • Blood/haematological Diseases

Disease

  • Atypical hemolytic uremic syndrome

  • Thrombotic microangiopathy

  • Hemolytic–uremic syndrome

  • Microvascular complications of diabetes 1

  • End stage renal disease

  • Renal disease

  • Venous thrombosis

Biomarkers

  • Creatinine

  • Lactate dehydrogenase

  • Platelet count

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved